NCT01707147View on ClinicalTrials.gov

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

3,219

Participants

Timeline

Start Date

November 16, 2012

Primary Completion Date

July 11, 2017

Study Completion Date

July 11, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Trajenta tablet

Linagliptin

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01707147 - A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter